Skip to main content
Advertisement
Advertisement

ALDX

ALDX logo

Aldeyra Therapeutics, Inc.

1.35
USD
Sponsored
-0.04
-3.23%
Sep 23, 15:54 UTC -4
Closed
exchange

After-Market

1.34

-0.01
-0.37%

ALDX Earnings Reports

Positive Surprise Ratio

ALDX beat 26 of 43 last estimates.

60%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.09
Implied change from Q2 26 (Revenue/ EPS)
--
/
--
Implied change from Q3 25 (Revenue/ EPS)
--
/
-30.77%

Aldeyra Therapeutics, Inc. earnings per share and revenue

On Aug 06, 2026, ALDX reported earnings of -0.09 USD per share (EPS) for Q2 26, beating the estimate of -0.09 USD, resulting in a 6.15% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.52% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.09 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Aldeyra Therapeutics, Inc. reported EPS of -$0.09, beating estimates by 6.15%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.52%, changed from $1.59 before the earnings release to $1.55 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 4 analysts, Aldeyra Therapeutics, Inc. is expected to report EPS of -$0.09 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement